Pharmatizing AI

Digital

In this off-the-stage interview from Frontiers Health 2025 discover how 'pharmatized' AI delivers smarter, faster, and more reliable innovation.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.